SHANGHAI – Wuxi Pharmatech (Cayman) Inc., a new breed of contract R&D organization, has completed the privatization process, requesting its stocks to stop trading on the New York Stock Exchange on Dec. 10. Wuxi’s chairman and chief executive, Ge Li, along with a consortium of private-equity investors paid $3.3 billion in cash to complete the deal. Wuxi first listed in the U.S. in 2007.